United States

People: Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

16 Mar 2018
Change (% chg)

$0.05 (+0.63%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Stiernholm, Niclas 

Dr. Niclas Stiernholm is President, Chief Executive Officer, Director of the Company. Dr. Stiernholm is the President and Chief Executive Officer of Trillium since April 9, 2013 and was the President and Chief Executive Officer of Trillium Privateco since 2002. He joined Trillium from YM BioSciences Inc. where he was Executive Vice President and Chief Scientific Officer. Dr. Stiernholm also sits on the board of Vasomune Therapeutics Inc. As President and Chief Executive Officer, Dr. Stiernholm is responsible for overseeing our strategic direction, executing business development plans and ensuring that our scientific programs remain funded and advance on schedule. As a director, Dr. Stiernholm participates in management oversight and helps to ensure compliance with our corporate governance policies and standards.

Basic Compensation

Total Annual Compensation, USD 1,716,790
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD 247,500
All Other, USD --
Fiscal Year Total, USD 1,964,290

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --